CN-122012713-A - Hepatocellular carcinoma prognosis evaluation marker TKFC and application thereof

Abstract

The invention discloses a hepatocellular carcinoma prognosis evaluation marker TKFC and application thereof, and belongs to the technical field of prognosis markers. By comparing the tumor tissues of patients with different prognosis, the invention finds that the more invasive HCC subtype presents a systematic imbalance of states, namely, reduced oxidative metabolism, represented by mitochondrial oxidative phosphorylation, tricarboxylic acid cycle, while the nuclear proliferation process associated with chromatin remodeling, cell cycle progression is abnormally active. This state of hypooxidative metabolism-hyperproliferative output may form the metabolic and epigenetic basis for malignant HCC. Low expression of TKFC is significantly associated with high risk clinical pathology features such as later tumor stage, higher incidence of vascular invasion, etc., and is an independent poor prognostic factor affecting the overall survival of the patient, suggesting that TKFC can be a prognostic biomarker for HCC.

Inventors

• Guo Wenpei
• LIU LIXIN
• HE JIEFENG
• YUE HAIYAN
• ZHOU CHUNAN

Assignees

• 山西医科大学

Dates

Publication Date

20260512

Application Date

20260211

Claims (6)

1. 1. Use of TKFC as marker for prognosis evaluation of hepatocellular carcinoma.
2. 2. The use according to claim 1, wherein the patient with TKFC high expression has a better prognosis.
3. 3. The application of a reagent for detecting TKFC expression quantity in preparing a product for prognosis evaluation of hepatocellular carcinoma.
4. 4. Use according to claim 3, wherein the product comprises a chip or a kit.
5. 5. The use according to claim 3, wherein the patient with TKFC high expression has a better prognosis.
6. 6. A kit for prognosis evaluation of hepatocellular carcinoma, characterized in that the kit comprises a reagent for detecting TKFC expression levels.

Description

Hepatocellular carcinoma prognosis evaluation marker TKFC and application thereof Technical Field The invention relates to the technical field of prognosis markers, in particular to a hepatocellular carcinoma prognosis evaluation marker TKFC and application thereof. Background Hepatocellular carcinoma (Hepatocellular carcinoma, HCC) is one of the leading causes of cancer-related death worldwide. Despite significant advances in prevention, screening, diagnosis and treatment techniques in recent years, the incidence and mortality of HCC remain high. Liver cancer usually occurs with long-term chronic liver disease or hepatitis virus infection, and the development process thereof takes decades. However, many patients are already at advanced stages of the disease at the time of diagnosis, and tumors are often associated with invasive metastases, and existing treatments are difficult to effectively control disease progression, resulting in an overall prognosis for HCC patients that remains undesirable. Currently, prognosis evaluation of HCC mainly relies on imaging examinations (e.g. CT, MRI) and liver function indicators (e.g. tumor markers such as AFP), but these methods still have shortcomings in terms of overall survival time, risk of recurrence and accuracy of prediction of metastasis trend. Imaging usually only can evaluate tumor progression after obvious lesions appear, and markers such as AFP are often interfered by non-neoplastic diseases such as hepatitis and liver cirrhosis, thereby leading to false positive or false negative results. Furthermore, some novel biomarkers are proposed, but most of them still do not enter clinical application, or their association with HCC progression and prognosis is not verified on a large scale, and it is difficult to meet the needs of personalized prognosis judgment and treatment strategy formulation. Based on the above-mentioned current situation, there is a need to find new, easily detectable molecular markers that are closely related to tumor malignancy and patient prognosis, to facilitate the personalized diagnosis and treatment of HCC. Disclosure of Invention The invention aims to provide a hepatocellular carcinoma prognosis evaluation marker TKFC and application thereof, which are used for solving the problems of the prior art, wherein the low expression of TKFC is obviously related to high-risk clinical pathological features such as later tumor stage, higher incidence of vascular invasion and the like, and is an independent bad prognosis factor affecting the total survival of a patient. In order to achieve the above object, the present invention provides the following solutions: The invention provides an application of TKFC serving as a hepatocellular carcinoma prognosis evaluation marker. Alternatively, TKFC high expressing patients have a better prognosis. The invention also provides application of the reagent for detecting TKFC expression quantity in preparation of a product for prognosis evaluation of hepatocellular carcinoma. Optionally, the product comprises a chip or a kit. Alternatively, TKFC high expressing patients have a better prognosis. The invention also provides a kit for prognosis evaluation of hepatocellular carcinoma, which comprises a reagent for detecting TKFC expression quantity. The invention discloses the following technical effects: by comparing the tumor tissues of patients with different prognosis, the invention finds that the more invasive HCC subtype presents a systematic imbalance of states, namely, reduced oxidative metabolism, represented by mitochondrial oxidative phosphorylation, tricarboxylic acid cycle, while the nuclear proliferation process associated with chromatin remodeling, cell cycle progression is abnormally active. This state of hypooxidative metabolism-hyperproliferative output may form the metabolic and epigenetic basis for malignant HCC. Notably TKFC exhibited significant low expression in this subtype, a finding that was validated in multiple independent public databases and clinical queues. Furthermore, low expression of TKFC is significantly associated with higher risk clinical pathology features such as later tumor stage, higher incidence of vascular invasion, etc., and is an independent poor prognostic factor affecting the overall survival of the patient, suggesting that TKFC may be a prognostic biomarker for HCC. Meanwhile, the tissue used in the detection and analysis of the invention is paraffin embedded HCC tissue, and the detected protein has stable property, is not easy to degrade, can be stored for a long time, is convenient for detection and has wide application prospect. Drawings In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and othe